Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase IIA Randomized, Double-Blind, Placebo-Controlled Study of LGD-4665 in Patients With Immune Thrombocytopenic Purpura (ITP) With an Open Label Extension

NCT00621894 is registered in ClinicalTrials.gov with GlaxoSmithKline as lead sponsor.

NCT NCT00621894
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00621894 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase IIA Randomized, Double-Blind, Placebo-Controlled Study of LGD-4665 in Patients With Immune Thrombocytopenic Purpura (ITP) With an Open Label Extension
Lead sponsor
GlaxoSmithKline
Phase
Phase 2
Overall status
Completed
Start date
March 15, 2008
Completion date
May 15, 2009
Enrollment
23 (actual)
Sites
15

Conditions

As the registry lists them; a condition with its own page is linked.

immune thrombocytopenic purpura